CSL Ltd. — Annual Report 2024

Aug 12, 2024

For immediate release

13 August 2024

==> picture [596 x 198] intentionally omitted <==

RESULTS PRESENTATION FOR THE FULL YEAR ENDED 30 JUNE 2024

Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY)

Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and Chief Financial Officer shortly. The live briefing will be webcast and can be viewed at https://edge.media-server.com/mmc/p/e6qpzs7g/

Please note that this link will expire after the webcast concludes.

A recording of the webcast will be made available later in the day at: https://investors.csl.com/investors/financial-results-and-information

Authorised for lodgment by:

==> picture [97 x 45] intentionally omitted <==

Fiona Mead Company Secretary

For further information, please contact:

Media:

Investors: Media: Chris Cooper Bernard Ronchi Stephen McKeon Jimmy Baker Head, Investor Relations Director, Investor Relations Director, Investor Relations Communications CSL Limited CSL Limited CSL Limited CSL Limited P: +61 455 022 740 P: +61 3 9389 3470 P: 61 402 231 696 P: +61 450 909 211 E: chris.cooper@csl.com.au E: bernard.ronchi@csl.com.au E: stephen.mckeon@csl.com.au E: jimmy.baker@csl.com.au

==> picture [122 x 98] intentionally omitted <==

Driven by Our Promise

2024 Full Year Results 13 August 2024

Zahra K.

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL ) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange ( ASX ), available at www.asx.com.au. This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", “project,” "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements . Factors that could cause actual results to differ materially include: the success or otherwise of CSL’s research and development activities; factors affecting CSL’s ability to successfully market and sell new and existing products, including decisions by regulatory authorities regarding approval of CSL’s products and regarding label claims, competitive developments affecting CSL’s products, and trade buying patterns; factors affecting CSL’s ability to collect plasma, and difficulties or delays in manufacturing; legislation or regulations affecting the manufacturing, distribution, pricing, or reimbursement of CSL’s products, market access for CSL’s products, environmental protection matters, or tax; litigation or government investigations; fluctuations in interest and currency exchange rates; acquisitions or divestitures; and CSL’s ability to protects its patents and other intellectual property.

.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

==> picture [110 x 11] intentionally omitted <==

----- Start of picture text -----

Driven by Our Promise
----- End of picture text -----

Except where otherwise noted, brand names designated by a or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

==> picture [74 x 56] intentionally omitted <==

CEO Overview

Financials

Outlook

CEO Overview

Paul McKenzie CEO & Managing Director

3

Delivered on Strategic Priorities in FY24

CSL Behring Strong growth, driven by Ig 14% (Ig 20%)[1]

CSL Seqirus Differentiated portfolio Market outperformance

CSL Vifor Drive synergies $100m+ p.a.

Rika Rollout

Yield Initiatives

84 Centres Horizon 1 and 2 I-Nomogram progressing FDA clearance to plan R&D pipeline Operating efficiency

R&D pipeline Operating efficiency Garadacimab, aTIVc 5.3%[1] HIZENTRA[®] DM (G&A/revenue) FILSPARI[®]

CSL Behring gross margin

120 bps[1]

Financial leverage

2.2x from 2.7x (Net Debt/EBITDA)

Geographic Expansion

HEMGENIX[®] Europe FERINJECT[®] China TAVNEOS[®] EU

PPE capital expenditure

31%

Strongly Positioned for Continued Annual Double-Digit Earnings Growth

==> picture [103 x 9] intentionally omitted <==

==> picture [74 x 56] intentionally omitted <==

4

CEO Overview

Financials

Outlook

Strong Performance[1]

CSL Behring

Strong growth across the portfolio driven by Ig

Revenue +11% NPATA[2,3] +15% NPAT[3] +25%

• Ig +20%, HAEGARDA[®] +12%, ALBUMIN[®] +12%, IDELVION[®] +10%

• • Gross margin +120 bps at CC

• Rika deployment on schedule for end-FY25

• I-Nomogram FDA clearance

• First patient dosed with HEMGENIX[®] in Europe

• Garadacimab US, EU and Japan regulatory submissions

==> picture [208 x 171] intentionally omitted <==

----- Start of picture text -----

$14,800m
----- End of picture text -----

Revenue Growth

Behring +14% Seqirus +4% Vifor nc[4]

CSL Seqirus

Solid performance driven by differentiated portfolio

• Seqirus +4% , FLUAD[®] +14%

• KOSTAIVE[®] COVID vaccine approved in Japan

• aTIVc phase III ongoing; sa-mRNA phase I influenza study

CSL Vifor

Evolving Iron market

• EU iron volumes robust

• Continued patient conversion to MIRCERA[®]

==> picture [103 x 9] intentionally omitted <==

• Strong Nephrology launches

==> picture [74 x 56] intentionally omitted <==

5

CEO Overview

Financials

Outlook

==> picture [198 x 110] intentionally omitted <==

Revenue $10,608m +14%[1]

	Revenue $10,608m +14%1
	6 Therapy Revenue ($m) Change1 Ig 5,666 +20% Albumin 1,209 +12% Haemophilia 1,313 +10% Specialty 1,940 +6%	Performance Major Brands • Strong performance across all geographies – PRIVIGEN®/ INTRAGAM®+21%, HIZENTRA®+19% • Significant patient demand in core indications • HIZENTRA® remains clear market leader in SCIG • Solid growth in all key geographies • Chinese demand robust • IDELVION®remains the standard of care, +10% – Leadership position in US, key EU markets and Japan • HEMGENIX®US and Europe infusions – Reimbursement approvals in EU, UK, Switzerland and Canada • HAEGARDA®+12% – Continue to add new patients whilst preserving patient base – Strong EU and Japan performance • KCENTRA®+5% – Continues to be gold standard for warfarin reversal – Some anticipated volume impact from competitor launch

==> picture [198 x 110] intentionally omitted <==

Operational Highlights

• Underlying fundamentals of plasma collection remain strong:

• Plasma donation growth momentum maintained

• Continued reduction in CPL

• Expanding geographic footprint

• Significant progress on digital transformation and enhanced focus on centre efficiencies

• Horizon 1 and 2 yield initiatives progressing to plan

• Gross margin recovery on track

==> picture [103 x 9] intentionally omitted <==

==> picture [478 x 196] intentionally omitted <==

----- Start of picture text -----

CEO Overview Financials Outlook
----- End of picture text -----

Rika Plasma Donation System

• Successfully rolled out to 84 centres

• On track to complete US rollout by end FY25

• Enhanced donor experience and reduced collection time

• I-Nomogram deployment throughout FY25

• Estimated to improve average donation yield by ~10%

==> picture [74 x 56] intentionally omitted <==

7

CEO Overview

Financials

Outlook

==> picture [199 x 107] intentionally omitted <==

Revenue $2,128m +4%[1]

Revenue $2,128m +4%1
Therapy Revenue ($m) Change1 Egg Based 140 (2%) Cell Culture 535 (11%) Adjuvanted Egg 1,040 +14% In License / Other 181 (13%) Pandemic 172 +9% Other Income 60 +146%	Performance Major Brands
	• Revenue growth in the northern hemisphere influenza market during a challenging season • Heightened recognition of benefits of differentiated product portfolio ‒ First season following US ACIP preferred recommendation for FLUAD®in 65+ ‒ FLUAD®>$1 billion revenue for first time
	• Transition to single dose Gardasil vaccine program • H5N8 avian flu preparedness
	• Successful renewal of UK APA tender
	• Includes COVID vaccine milestones in Japan

==> picture [103 x 9] intentionally omitted <==

==> picture [74 x 56] intentionally omitted <==

8

CEO Overview

Financials

Outlook

==> picture [199 x 107] intentionally omitted <==

Operational Highlights

Product Innovation

Seasonal Influenza Products

• FLUCELVAX[®] 6-month+ age extension approved in EU, UK, Australia and New Zealand

• Phase III clinical study commenced for aTIVc

• Regulatory approval for world-first samRNA COVID vaccine

• FLUAD[®]

• Japanese approval for KOSTAIVE[®]

• ‒

• 50-year+ age extension approved in the EU

  • Positive 12m durability data published in The Lancet

• Received preferential recommendation in Canada for 65+

• Phase I trial for sa-mRNA in seasonal and pandemic influenza

• population

Pandemic Influenza

• UK Advance Purchase Agreement awarded solely to CSL Seqirus

• Selected by BARDA and HERA for delivery of H5N8 vaccine

Tullamarine Certificate of Occupancy

==> picture [103 x 9] intentionally omitted <==

==> picture [74 x 56] intentionally omitted <==

9

CEO Overview

Financials

Outlook

==> picture [199 x 105] intentionally omitted <==

Revenue $2,064m

Therapy	Revenue ($m)	Performance	Major Brands
		• Robust volume growth in evolving iron market
Iron	1,018	– China FERINJECT® launch
		– US step edit pressure
		• MIRCERA®
		– Strong ESA performance as US patient conversion	a
		continued
Nephrology: Dialysis	786	• KAPRUVIA® – Strong performance in Germany, France and Austria	b	c
		• VELPHORO®
		– US inventory adjustment and China reimbursement
		• TAVNEOS®
Nephrology: Non-Dialysis	200	– Strong performance in all EU launch markets • VELTASSA® – Growth in US and EU markets			d
		– Paediatric indication approved in US and EU

a. Licensed from F. Hoffman-La Roche AG; b. Licensed from Pfizer Inc.; c. Licensed from Cara Therapeutics, Inc.; d. Rights to EU, UK, Japan and certain other countries licensed from ChemoCentryx, Inc., a wholly owned subsidiary of Amgen, Inc.

==> picture [103 x 9] intentionally omitted <==

==> picture [74 x 56] intentionally omitted <==

10

CEO Overview

Financials

Outlook

Financials

Joy Linton CFO

==> picture [74 x 56] intentionally omitted <==

11

CEO Overview

Financials

Outlook

NPATA[2,3]

$3,008m $101m FX $2,907m $2,610m FY23 NPATA FY24 NPATA @ CC

	FY23	FY24	Change
	Rep4	@ CC	%1
NPATA	$2,610m	$3,008m	+15%
Acquired intellectual property amortisation	($235m)	($298m)
Acquisition related adjustments	($353m)	($83m)
Tax	$85m	$59m
NPATA Attributable to NCI	$137m	$132m
NPAT	$2,244m	$2,818m	+26%
NPAT Attributable to NCI	($50m)	($73m)
NPATto CSL equity holders	$2,194m	$2,745m	+25%

==> picture [74 x 56] intentionally omitted <==

12

CEO Overview

Financials

Outlook

Segment Financial Highlights

Path to Gross Margin Recovery

CSL Behring

US$ millions reported	FY23	FY24	Change % at CC 1
Sales	8,968	10,334	15%
Other Revenue Total Revenue Gross Profit5 GP %5 Sales & Marketing	322 9,290 4,561 49.1% 804	274 10,608 5,275 50.3%1 903	(15%) 14% 17% 12%
Operating Result	3,757	4,372	18%
Operating Segment %5	40.4%	41.2%

==> picture [103 x 9] intentionally omitted <==

• Optimise donor fees

• • RIKA benefits • Centre efficiencies

CPL Reduction

• HEMGENIX[®]

• • HIZENTRA[®] PFS • Garadacimab

New Products

==> picture [210 x 109] intentionally omitted <==

----- Start of picture text -----

Asp Mix Shift
Key Contributors
----- End of picture text -----

• HIZENTRA[®] v PRIVIGEN[®]

• • Geographic mix

Ig Yield Improvements

• Horizon 1

• Increased volume

• • Variable v fixed costs • Manufacturing efficiencies

Scale & Efficiency Measures

Excludes potential benefits of Horizon 2 initiatives

==> picture [74 x 56] intentionally omitted <==

Illustrative only

13

CEO Overview

Financials

Outlook

Segment Financial Highlights

CSL Seqirus

CSL Seqirus
US$ millions reported	FY23	FY24	Change % at CC 1
Sales	1,851	1,896	1%
Other Revenue	180	232	28%
Total Revenue	2,031	2,128	4%
Gross Profit5	1,259	1,318	4%
GP %5	62.0%	62.3%1
Sales & Marketing	187	196	8%
Operating Result5	1,072	1,122	4%
Operating Segment %5	52.8%	52.7%

==> picture [103 x 9] intentionally omitted <==

CSL Vifor

CSL Vifor
US$ millions reported	FY234	FY24
Sales	1,957	2,029
Other Revenue	32	35
Total Revenue	1,989	2,064
Gross Profit5	1,411	1,413
GP %5	70.9%	68.1%1
Sales & Marketing	490	457
Operating Result5	921	956
Operating Segment %5	46.3%	46.3%

==> picture [74 x 56] intentionally omitted <==

14

CEO Overview

Financials

Outlook

CSL Group Financial Highlights

US$ Millions	FY23 Rep	FY24 Rep	FY24 at CC 1	Change % 1
Total Revenue Gross Profit5 GP %5	13,310 7,231 54.3%	14,800 8,006 54.1%	14,744 8,030 54.5%	11% 11%
Sales & Marketing Operating Result5 R&D5	1,481 5,750 1,266	1,556 6,450 1,428	1,549 6,481 1,421	5% 13% 12%
G&A5 Finance (Net)	827 406	825 437	776 436	(6%) 7%
NPATA3	2,610	2,907	3,008	15%
ETR % ROIC Cashflow From Ops	15.5% 12.2% 2,601	19.2% 10.5% 2,764	18.4%	6%Y
NPATA EPS3($)	5.41	6.02		11%Y
NPAT EPS3($) DPS ($)	4.55 2.36	5.47 2.64		20%Y 12%Y

Y. At reported currency

==> picture [103 x 9] intentionally omitted <==

R&D

• Growth in line with sales

• FY25 R&D expenditure ~10% of revenue

• G&A

• Efficiencies driven by centralisation of Enabling Functions and reduced FX impact

Finance

• Favourable debt structure limited impact of higher rates

Tax

• Higher ETR due to geographic profit mix and increased UK tax rate

ROIC

• Full year consolidation impact of CSL Vifor

• Improvement to be driven by profit growth

• Cashflow from Operations

• Increase in cash earnings from growth in sales, partially offset by increase in working capital

==> picture [74 x 56] intentionally omitted <==

15

CEO Overview

Financials

Outlook

Capital Expenditure

Delivering capital-efficient growth

US$m
- 200 400 600 800 1,000 1,200 1,400	0% 2% 4% 6% 8% 10% 12% 14% FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 Capex % of Rev % of Revenue

Capital Expenditure for Property, Plant & Equipment

==> picture [103 x 9] intentionally omitted <==

• Reduction in capex follows a period of significant capacity expansion required to meet increasing market demand

• Prioritising yield initiatives for majority of supply expansion through medium-term

• FY25 capex anticipated to be ~$700-800m

==> picture [74 x 56] intentionally omitted <==

16

CEO Overview

Financials

Outlook

Cash Conversion Cycle

Days

250

==> picture [474 x 274] intentionally omitted <==

----- Start of picture text -----

215
201 192 199
200 196
186 187
10 year
174 174 average
160
150
100
FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24
----- End of picture text -----

==> picture [103 x 9] intentionally omitted <==

Focus on working capital efficiency

• Cash conversion has improved from pandemic-driven peak

• Increase in FY24 due to timing of trade receivables

• Working capital efficiency is a strategic priority through mid-term

==> picture [74 x 56] intentionally omitted <==

17

CEO Overview

Financials

Outlook

Outlook Paul McKenzie CEO & Managing Director

18

FY25 Outlook

CSL Behring

CSL Seqirus

• Continued market outperformance from differentiated portfolio

• Underlying patient demand for Ig in core indications remains strong

• sa-mRNA COVID vaccine development

• Positive reimbursement decisions support HEMGENIX[®] growth

  • Commercialisation of KOSTAIVE[® ] in Japan

  • Preparation for EU and US submissions

• H5N8 avian influenza preparedness

• Preparing for Garadacimab regulatory outcome and launch

CSL Vifor

• Complete roll-out Rika and I-Nomogram

• Well positioned for iron competition

• Maintain nephrology launch momentum

• Horizon 1 and 2 yield initiatives ongoing

• Collaboration activities across CSL commercial and operations

• Improving gross margin

• Continue to advance Patient Blood Management with CSL Behring

FY25 FX impact estimated to be a headwind of approximately $50m if current rates remain unchanged for the remainder of the financial year

==> picture [103 x 9] intentionally omitted <==

==> picture [314 x 332] intentionally omitted <==

Revenue Growth

~ 5 - 7% @CC[1]

NPATA Growth

~ 10 – 13% @CC[1,3] to ~$3.2 – $3.3b @CC[1.3]

==> picture [74 x 57] intentionally omitted <==

19

==> picture [122 x 108] intentionally omitted <==

==> picture [120 x 14] intentionally omitted <==

----- Start of picture text -----

CSL Contacts
----- End of picture text -----

Chris Cooper Investor Relations  +61 455 022 740 chris.cooper@csl.com.au Bernard Ronchi Investor Relations  +61 3 9389 3470 bernard.ronchi@csl.com.au

Stephen McKeon Investor Relations  +61 402 231 696 stephen.mckeon@csl.com.au

Notes

(#) Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance for the Group. This is done in three parts: a) by converting the current year net profit of entities in the group that have reporting currencies other than US Dollars, at the rates that were applicable to the prior comparable period (translation currency effect); b) by restating material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred in the prior comparable period (transaction currency effect); and c) by adjusting for current year foreign currency gains and losses. The sum of translation currency effect, transaction currency effect and foreign currency gains and losses is the amount by which reported net profit is adjusted to calculate the operational result.

General Disclaimer Non-IFRS

There are references to IFRS (International Financial Reporting Standards) and non-IFRS financial information in this document. Non-IFRS financial measures are financial measures other than those defined or specified under any relevant accounting standard and may not be directly comparable with other companies’ information. Non-IFRS financial measures are used to enhance the comparability of information between reporting periods, and enable further insight and a different perspective into the financial performance. Non-IFRS financial information should be considered in addition to, and is not intended to be a substitute for, IFRS financial information and measures. Non-IFRS financial measures are not subject to audit or review.

==> picture [103 x 9] intentionally omitted <==

Summary NPAT attributable to members of parent entity

of parent entity
Reportednetprofit after tax	$2,642m
Currency effect	$103m
Constant currency net profit after tax*	$2,745m

Average exchange rates for major currencies for full year ended 30 June 2023/ 30 June 2024 include: USD/EUR (0.96/0.92), USD/AUD (1.49/1.52), USD/CHF (0.94/0.89), USD/CNY (6.95/7.22) and USD/GBP (0.83/0.79).

	Summary NPATA2attributable to
	members of the parent entity	US$m
	Reported net profit after tax	2,642
	Amortisation of acquired intellectual property	241
	Unwind of inventory fair value uplift	20
	Acquisition and integration costs	54
	Income tax credit on above adjustments	(50)
	NPATA2 attributable to members of the parent entity	2,907
	Currency effect attributable to members of the parent entity	101
	Constant Currency# NPATA2 attributable to members of the parent entity	3,008

Summary Revenue

Summary Revenue
Reported revenue	$14,800m
Currency effect	($56m)
Constant currency revenue*	$14,744m

• *Constant currency net profit after tax and constant currency sales have not

• been audited or reviewed in accordance with Australian Auditing Standards.

Footnotes

1. Percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail

2. NPATA is defined as the statutory NPAT before impairment and amortisation of acquired IP, business acquisition and integration costs and unwind of the inventory fair value uplift

4. Attributable to the shareholders of CSL Limited

5. FY23 includes ~11 months of CSL Vifor contribution

6. Underlying results have been adjusted to exclude impairment and amortisation of acquired intellectual property, business acquisition and integration costs and unwind of the inventory fair value uplift

NPATA to NPAT FY25 outlook

NPATA to NPAT adjustments, attributable to:	Group	Group	CSL shareholders (post tax)	CSL shareholders (post tax)
	FY25	FY24	FY25	FY24
	Outlook	at CC	outlook	at CC
Amortisation of acquired intellectual property	370 +/- 10%	298	260 +/- 10%	201
Acquisition and integration costs	-	53	-	41
Unwind of inventory fair value uplift	-	30	-	20
Income tax credit on above adjustments	(60) +/- 10%	(60)	-	-
Total	310 +/- 10%	321	260+/- 10%	262

==> picture [74 x 56] intentionally omitted <==

21

Appendix

==> picture [103 x 9] intentionally omitted <==

==> picture [74 x 56] intentionally omitted <==

22

Appendix A CSL Behring – Key Products

CSL Behring	Therapy Group	Sales $m	Change1%
Privigen	IVIG	3,624	27%
Hizentra	SCIG	1,961	19%
Albumin Idelvion	Albumin Haemophilia	1,209 777	12% 10%
Kcentra	Specialty	702	5%
Haegarda	Specialty	491	12%
Berinert	Specialty	242	(6%)
Haemocomplettan	Specialty	233	6%
Humate	Haemophilia	184	8%
Haemate	Haemophilia	118	10%

==> picture [103 x 9] intentionally omitted <==

FY24 Revenue By Therapy Group $m

		IVIG SCIG	$3,705 $1,961	35% 18%
	CSL	Albumin	$1,209	11%
	Behring
		Recombinants Coag	$883	8%
		Plasma Coag	$398	4%
		Peri-Operative Bleeding	$1,023	10%
		Other Specialty	$917	9%
		Other	$512	5%

==> picture [74 x 57] intentionally omitted <==

23

Appendix B CSL Seqirus & CSL Vifor – Key Products

FY24 Revenue By Therapy Group $m

CSL Seqirus	Therapy Group	Sales $m	Change1%
Fluad Flucelvax Afluria	Adjuvanted Cell culture Egg-based	1,040 535 140	14% (11%) (2%)
CSL Vifor	Therapy Group	Sales $m
Ferinject / Injectafer Mircera Venofer	Iron Dialysis Iron	759 619 173
Velphoro	Dialysis	109
Veltassa	Non Dialysis	138
Maltofer	Iron	82
Tavneos	Non Dialysis	60

==> picture [103 x 9] intentionally omitted <==

==> picture [348 x 274] intentionally omitted <==

----- Start of picture text -----

Cell Culture $535 25%
Adjuvanted $1,040 49%
Egg Based $140 7%
CSL
Seqirus In License $181 9%
Pandemic $172 8%
Other Income $60 2%
Iron $1,018 49%
Dialysis $786 38%
CSL
Vifor Non Dialysis $200 10%
Other $60 3%
----- End of picture text -----

==> picture [74 x 57] intentionally omitted <==

24

Significant progress made with CSL’s Sustainability Strategy

Sustainability strategy refreshed

Moving to 100% renewable electricity in Australia and Europe

• Repositioned with focus on healthier communities and healthier environment

• All Australian facilities from Jan 2025

==> picture [261 x 132] intentionally omitted <==

• Strong progress on Scope 3 emissions engagement

• Validation by the Science Based Targets initiative pending

Donor experience Energy Patient experience Water Access and affordability Waste Talent and culture Supplier

CSL’s sustainability vision is for a healthier world

==> picture [103 x 9] intentionally omitted <==

==> picture [313 x 286] intentionally omitted <==

Strategic themes across focus areas

Health equity & empowerment

==> picture [38 x 45] intentionally omitted <==

Embed an inclusive culture where all backgrounds and perspectives belong, develop, and thrive

Inclusion & belonging

==> picture [38 x 38] intentionally omitted <==

Everyone deserves the opportunity to achieve and maintain their highest level of health and well-being

==> picture [74 x 57] intentionally omitted <==

25